Capecitabine/Temozolomide Chemotherapy in Metastatic Neuroendocrine Tumors: Response Rate and Survival by Grade

被引：0
|
作者：
Thomas, Katharine [1 ]
Griffin, Ryan [1 ,2 ]
Voros, Brianne [2 ,3 ]
Boudreaux, J. Phillip [2 ,3 ]
Thiagarajan, Ramcharan [2 ,3 ]
Woltering, Eugene [2 ,3 ]
Ramirez, Robert [1 ,2 ]
机构：
[1] Ochsner Med Ctr, Baton Rouge, LA USA
[2] Ochsner Kenner, Kenner, LA USA
[3] Louisiana State Univ, Baton Rouge, LA 70803 USA
来源：
PANCREAS | 2019年 / 48卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：453 / 453
页数：1
相关论文
共 50 条
  • [1] The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors
    Ramirez, Robert A.
    Beyer, David T.
    Chauhan, Aman
    Boudreaux, J. Philip
    Wang, Yi-Zarn
    Woltering, Eugene A.
    ONCOLOGIST, 2016, 21 (06): : 671 - 675
  • [2] Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
    Strosberg, Jonathan
    Cives, Mauro
    Brelsford, Marjorie
    Black, Michael
    Meeker, Alan
    Ghayouri, Masoumeh
    CANCER RESEARCH, 2015, 75
  • [3] Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
    Strosberg, Jonathan R.
    Cives, Mauro
    Brelsford, Marjorie
    Black, Michael
    Meeker, Alan
    Ghayouri, Masoumeh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Identification of Response Predictors to Capecitabine/Temozolomide in Metastatic Pancreatic Neuroendocrine Tumors
    Cives, Mauro
    Ghayouri, Masoumeh
    Brelsford, Marjorie
    Black, Michael
    Rizzo, Anthony
    Meeker, Alan
    Strosberg, Jonathan
    PANCREAS, 2016, 45 (03) : 473 - 474
  • [5] A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors
    Rego, I.
    Pontes, F.
    Carvalho, J.
    Pratas, E.
    Chaves, A.
    Martins, R.
    Couto, J.
    Ribeiro, J.
    Rodrigues, F.
    Sousa, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
    Cives, M.
    Ghayouri, M.
    Morse, B.
    Brelsford, M.
    Black, M.
    Rizzo, A.
    Meeker, A.
    Strosberg, J.
    ENDOCRINE-RELATED CANCER, 2016, 23 (09) : 759 - 767
  • [7] Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series
    Strosberg, Jonathan
    Saranga-Perry, Vita
    Morse, Brian
    Centeno, Barbara
    Kvols, Larry
    PANCREAS, 2013, 42 (02) : 383 - 384
  • [8] Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
    Squires, Malcolm
    Worth, Patrick
    Konda, Bhavana
    Dillhoff, Manisha Shah Mary
    Abdel-Misih, Sherif
    Pawlik, Timothy
    Schmidt, Carl
    Poultsides, George
    Cloyd, Jordan
    PANCREAS, 2020, 49 (03) : 488 - 488
  • [9] Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series
    Saranga-Perry, Vita
    Morse, Brian
    Centeno, Barbara
    Kvols, Larry
    Strosberg, Jonathan
    NEUROENDOCRINOLOGY, 2013, 97 (04) : 318 - 321
  • [10] The Role of Capecitabine/Temozolomide (CAPTEM) in Metastatic Neuroendocrine Tumors: A Neuroendocrine Tumor Program Experience
    Ramirez, Robert A.
    Chauhan, Aman
    Beyer, David T.
    Boudreaux, J. Philip
    Wang, Yi-Zarn
    Woltering, Eugene A.
    PANCREAS, 2016, 45 (03) : 480 - 480
12345